ArticleCardiovascular diabetology2018
Both pre-frailty and frailty increase healthcare utilization and adverse health outcomes in patients with type 2 diabetes mellitus.
Article in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 4 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Diabetes/metabolism research and reviews · 2026Pooled it
- Prevalence and risk factors of frailty in older adults with diabetes: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Frailty measurement, prevalence, incidence, and clinical implications in people with diabetes: a systematic review and study-level meta-analysis.The lancet. Healthy longevity · 2020Pooled it
- Relationship between frailty and mortality, hospitalization, and cardiovascular diseases in diabetes: a systematic review and meta-analysis.Cardiovascular diabetology · 2019Pooled it
- Trial
- Serum Periostin as a Complementary Biomarker of Frailty in Type 2 Diabetes: A Pilot Study Using the FRAIL Scale.International journal of molecular sciences · 2026Article
- Phase angle, extracellular to intracellular water ratio, and advanced glycation end products according to four sarcopenia categories and in relation to muscle strength/mass in elderly out-patients with diabetes.Diabetology international · 2026Article
- Associations of frailty with the incidence and progression trajectory of cardiometabolic-kidney multimorbidity: insights from multi-state modelling.Journal of global health · 2026Article
- Sarcopenia, sarcopenic obesity, and frailty in individuals with chronic kidney disease: a comprehensive review.Kidney research and clinical practice · 2026Article
- Differential associations of febuxostat and allopurinol with incident and worsening frailty risk in nephrology patients.International journal of medical sciences · 2026Article
- Sleep Disorders Predict Frailty Progression in Type 2 Diabetes Mellitus: Findings from a Cohort of 20,562 Patients.Diabetes & metabolism journal · 2026Article
- What older adults say about participating in health-promoting activities to prevent frailty: a qualitative study.BMC geriatrics · 2025Article
- Frailty Among Patients With ADPKD.Kidney international reports · 2025Article
- Practical Considerations in the Management of Frail Older People with Diabetes.Diseases (Basel, Switzerland) · 2025Review
- Article
- Association of iodized salt intake with the risk of physical frailty in patients with type 2 diabetes.The journal of nutrition, health & aging · 2025Article
- Frailty Assessment Tools Influence the Outcome Associations Among Patients With Diabetes: A Retrospective Cohort Study.JACC. Asia · 2025Article
- Frailty incidence by diabetes treatment regimens in older adults with diabetes mellitus in the ASPirin in Reducing Events in the Elderly Study.GeroScience · 2025Observational
- Association of frailty index with all-cause and cardiovascular mortality with different diabetic status: NHANES 1999-2018.Acta diabetologica · 2025Article
- Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) correlates with accelerated aging and earlier appearance of geriatric phenotypes, including frailty. However, whether pre-frailty or frailty predicts greater healthcare utilization in diabetes patients is unclear.
methodsFrom the Longitudinal Cohort of Diabetes Patients in Taiwan (n = 840,000) between 2004 and 2010, we identified 560,795 patients with incident type 2 DM, categorized into patients without frailty, or with 1, 2 (pre-frail) and ≥ 3 frailty components, based on FRAIL scale (Fatigue, Resistance, Ambulation, Illness, and body weight Loss). We examined their long-term mortality, cardiovascular risk, all-cause hospitalization, and intensive care unit (ICU) admission.
resultsAmong all participants (56.4 ± 13.8 year-old, 46.1% female, and 84.8% community-dwelling), 77.8% (n = 436,521), 19.2% (n = 107,757), 2.7% (n = 15,101), and 0.3% (n = 1416) patients did not have or had 1, 2 (pre-frail), and ≥ 3 frailty components (frail), respectively, with Fatigue and Illness being the most common components. After 3.14 years of follow-up, 7.8% patients died, whereas 36.6% and 9.1% experienced hospitalization and ICU stay, respectively. Cox proportional hazard modeling discovered that patients with 1, 2 (pre-frail), and ≥ 3 frailty components (frail) had an increased risk of mortality (for 1, 2, and ≥ 3 components, hazard ratio [HR] 1.05, 1.13, and 1.25; 95% confidence interval [CI] 1.02-1.07, 1.08-1.17, and 1.15-1.36, respectively), cardiovascular events (HR 1.05, 1.15, and 1.13; 95% CI 1.02-1.07, 1.1-1.2, and 1.01-1.25, respectively), hospitalization (HR 1.06, 1.16, and 1.25; 95% CI 1.05-1.07, 1.14-1.19, and 1.18-1.33, respectively), and ICU admission (HR 1.05, 1.13, and 1.17; 95% CI 1.03-1.07, 1.08-1.14, and 1.06-1.28, respectively) compared to non-frail ones. Approximately 6-7% risk elevation in mortality and healthcare utilization was noted for every frailty component increase.
conclusionPre-frailty and frailty increased the risk of mortality and cardiovascular events, and entailed greater healthcare utilization in patients with type 2 DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.